Safer Metal Based Imaging Agents

更安全的金属基显像剂

基本信息

  • 批准号:
    10709659
  • 负责人:
  • 金额:
    $ 6.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-30 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary Metals offer a stunning array of properties that can be exploited for biomedical purposes. Metals such as platinum, ruthenium and copper are used in chemotherapy. Yttrium and indium are used in radiotherapy. Neodymium, europium and terbium are finding application in luminescent probes. Copper, gallium and whole host of other metal isotopes can be used in PET and SPECT imaging. Gadolinium is widely used in MRI, while manganese is proposed as an alternative. However, these advantageous properties come with a price: the risk of metal ion toxicity. To make metals safe for most in vivo application they must be held tightly in a coordinating ligand. The purpose of this ligand is to shield the body from the metal ion, avoiding the body’s natural metal transport and storage systems and permit the metallo-pharmaceutical to perform as intended. But most crucially this ligand allows the metal ion to be excreted. Broadly speaking, metals fall into one of two categories: 1) Those to which evolving life was exposed and took advantage: the essential minerals. And 2) those to which evolving life had no exposure and are not normally found in lifeforms: the xenobiotic metals (which includes many of the heavy metals). One might expect that these two classes of metal ion would be fundamentally different, but, they share a common feature in biology: neither can be excreted. Xenobiotic metals because these pathways never developed and essential minerals because they are too valuable to lose. Clearly metal ions escaping from the ligands in which they are administered represents a serious problem and risk to human health. Once out of the ligand they are incorporated into the body and can never leave. This means that the complexes formed between metal and ligand must be as robust as possible. Although there are some excellent ligand systems already in use in clinical medicine, concern continues to exist about the release of metal ions from these ligand structures. The aim of this small project is to investigate whether a small, and comparatively simple, modification to these ligand systems would lead to substantial improvements in the robustness of the complex. If so it will have the effect of paving the way to yet safer ligand systems for metals in biomedical applications.
项目摘要 金属提供了一系列令人惊叹的特性,可以用于生物医学目的。金属,如 铂、钚和铜被用于化疗。在放射治疗中用到了钇和铟。 钕、Eu和Tb在发光探针中得到了应用。铜、镓和全铜 其他金属同位素的主体可用于正电子发射计算机断层扫描和SPECT成像。Gd在核磁共振中被广泛使用,而 建议将锰作为一种替代品。然而,这些有利的房产是有代价的:风险 金属离子毒性。 为了使金属对大多数活体应用是安全的,它们必须紧紧地保持在一个配位配体中。目的 这种配体的作用是保护身体免受金属离子的伤害,避免人体自然的金属运输和储存 系统,并允许金属药物发挥预期的作用。但最关键的是,这种配体允许 需要排泄的金属离子。 广义地说,金属分为两类:1)进化生命所接触到的金属 优势:精华矿物质。2)那些进化的生命没有接触到的,也不是正常的 发现于生命形式中:外来金属(包括许多重金属)。人们可能会想到,这些 两类金属离子将从根本上不同,但它们在生物学上有一个共同的特征:都不是 可以被排泄出来。异种生物金属,因为这些途径从未开发过,而必需矿物质是因为 它们太有价值了,不能丢。 显然,金属离子从给药的配体中逃逸是一个严重的问题, 对人类健康的威胁。一旦离开配体,它们就会结合到体内,永远不能离开。这 这意味着金属和配体之间形成的络合物必须尽可能地坚固。尽管有 一些优秀的配基系统已经在临床医学中使用,对释放的担忧继续存在 这些配基结构中的金属离子。这个小项目的目的是调查一个小的,和 相对简单的是,对这些配基系统的修改将导致对 复合体的健壮性。如果是这样的话,它将为更安全的金属配体系统铺平道路 在生物医学方面的应用。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
α-Aryl substituted GdDOTA derivatives, the perfect contrast agents for MRI?
  • DOI:
    10.1039/d3cc05989h
  • 发表时间:
    2024-01-09
  • 期刊:
  • 影响因子:
    4.9
  • 作者:
    Maier,Karley B.;Rust,Lauren N.;Woods,Mark
  • 通讯作者:
    Woods,Mark
Diastereoselective Synthesis of α-Aryl-Substituted LnDOTA Chelates from Achiral Starting Materials by Deracemization Under Mild Conditions.
在温和条件下通过去消旋化从非手性起始材料非对映选择性合成 α-芳基取代的 LnDOTA 螯合物。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK WOODS其他文献

MARK WOODS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK WOODS', 18)}}的其他基金

Safer Metal Based Imaging Agents
更安全的金属基显像剂
  • 批准号:
    10576181
  • 财政年份:
    2022
  • 资助金额:
    $ 6.95万
  • 项目类别:
Improving the Effectiveness of ParaCEST Agents by Controlling the Conformation
通过控制构象提高 ParaCEST 药物的有效性
  • 批准号:
    8033175
  • 财政年份:
    2010
  • 资助金额:
    $ 6.95万
  • 项目类别:
Improving the Effectiveness of ParaCEST Agents by Controlling the Conformation
通过控制构象提高 ParaCEST 药物的有效性
  • 批准号:
    7874779
  • 财政年份:
    2010
  • 资助金额:
    $ 6.95万
  • 项目类别:
TOWARDS A SINGLE INJECTION METHOD OF DETERMINING IN VIVO PH BY MRI
通过 MRI 确定体内 PH 值的单次注射方法
  • 批准号:
    7357912
  • 财政年份:
    2006
  • 资助金额:
    $ 6.95万
  • 项目类别:
Rational control of water exchange in Gd3+ complexes
Gd3配合物中水交换的合理控制
  • 批准号:
    6783808
  • 财政年份:
    2004
  • 资助金额:
    $ 6.95万
  • 项目类别:
Rational control of water exchange in Gd3+ complexes
Gd3配合物中水交换的合理控制
  • 批准号:
    6864434
  • 财政年份:
    2004
  • 资助金额:
    $ 6.95万
  • 项目类别:
Copper Complexes for Cancer Imaging and Therapy
用于癌症成像和治疗的铜配合物
  • 批准号:
    6687219
  • 财政年份:
    2003
  • 资助金额:
    $ 6.95万
  • 项目类别:

相似国自然基金

Journal of Integrative Plant Biology
  • 批准号:
    31024801
  • 批准年份:
    2010
  • 资助金额:
    24.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

An engineering biology approach for sustainable production of omega 3 and pigments from microalgae
一种利用微藻可持续生产 omega 3 和色素的工程生物学方法
  • 批准号:
    10107393
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Launchpad
FLF Next generation atomistic modelling for medicinal chemistry and biology
FLF 下一代药物化学和生物学原子建模
  • 批准号:
    MR/Y019601/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Fellowship
Sustainable Style for Clean Growth: Innovating Textile Production through Engineering Biology
清洁增长的可持续方式:通过工程生物学创新纺织品生产
  • 批准号:
    BB/Y007735/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Research Grant
Preventing Plastic Pollution with Engineering Biology (P3EB) Mission Hub
利用工程生物学 (P3EB) 任务中心预防塑料污染
  • 批准号:
    BB/Y007972/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Research Grant
GlycoCell Engineering Biology Mission Hub: Transforming glycan biomanufacture for health
GlycoCell 工程生物学任务中心:转变聚糖生物制造以促进健康
  • 批准号:
    BB/Y008472/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Research Grant
Postdoctoral Fellowship: STEMEdIPRF: Understanding instructor and student concepts of race to measure the prevalence of race essentialism in biology education
博士后奖学金:STEMEdIPRF:了解教师和学生的种族概念,以衡量生物教育中种族本质主义的流行程度
  • 批准号:
    2327488
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Standard Grant
CAREER: Hybridization and radiation: Integrating across phylogenomics, ancestral niche evolution, and pollination biology
职业:杂交和辐射:系统基因组学、祖先生态位进化和授粉生物学的整合
  • 批准号:
    2337784
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Continuing Grant
Collaborative Research: IMPLEMENTATION: Broadening participation of marginalized individuals to transform SABER and biology education
合作研究:实施:扩大边缘化个人的参与,以改变 SABER 和生物教育
  • 批准号:
    2334954
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Standard Grant
Collaborative Research: REU Site: Summer Undergraduate Research Program in RNA and Genome Biology (REU-RGB)
合作研究:REU 网站:RNA 和基因组生物学暑期本科生研究计划 (REU-RGB)
  • 批准号:
    2349255
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Continuing Grant
REU Site: Nature's machinery through the prism of Physics, Biology, Chemistry and Engineering
REU 网站:通过物理、生物、化学和工程学的棱镜观察自然的机器
  • 批准号:
    2349368
  • 财政年份:
    2024
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了